NYSE · SAB
Financial Services · Asset Management
$25.62
Down-$0.03 (-0.12%)
Updated Sep 16, 2026, 5:30 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SAB does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SAB.
SAB research
Company profile and research snapshot.
Saratoga Investment Corp. provides debt financing and equity capital to middle market companies.
Consensus and target data currently published for this company.
No generated briefing is available yet.
globenewswire.com · Nov 13, 2025
MIAMI, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial results for the third quarter ending September 30, 2025, and provided business highlights.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SAB.
No results
No recent SID articles mention SAB.
